RESEARCH ARTICLE

Endothelial-Mesenchymal Transition in Vascular Calcification of Ins2Akita/+ Mice

Pierre J. Guihard1, Jiayi Yao1, Ana M. Blazquez-Medela1, Luisa Iruela-Arispe2,3, Kristina I. Bostrom1,2,*, Yucheng Yao1,3*

1 Division of Cardiology, David Geffen School of Medicine at UCLA, Los Angeles, California, United States of America, 2 The Molecular Biology Institute at UCLA, Los Angeles, California, United States of America, 3 Jonsson Comprehensive Cancer Center at UCLA, Los Angeles, California, United States of America

* yyao@mednet.ucla.edu (YY); kbostrom@mednet.ucla.edu (KB)

Abstract

Endothelial-mesenchymal transition (EndMT) drives endothelium to contribute to normal development and disease processes. Here, we report that EndMTs occur in the diabetic endothelium of Ins2Akita/wt mouse, and show that induction of sex determining region Y-box 2 (Sox2) is a mediator of excess BMP signaling that results in activation of EndMTs and increased vascular calcification. We also find an induction of a complex of serine proteases in the diabetic endothelium, required for the up-regulation of Sox2. Our results suggest that EndMTs contribute to vascular calcification in diabetic arteries.

Introduction

Endothelial-mesenchymal transition (EndMT) is a process through which endothelial cells (ECs) transit into mesenchymal stem cells and gain plasticity for non-EC lineages [1, 2]. Previous studies have shown that EndMTs occur in organogenesis, such as neural crest formation and cardiogenesis [3, 4]. In disease, EndMTs have been demonstrated to contribute to the progress of pulmonary hypertension [5], atherosclerosis [6], cardiac and renal fibrosis [7, 8], fibrodysplasia ossificans progressive [9], and cancer progression [10]. Recently, our studies revealed a significant contribution of EndMTs in vascular calcification caused by deficiency of Matrix Gla protein (MGP), a well-established model of vascular calcification [2, 11, 12]. We showed that EndMTs drive endothelium to a mesenchymal state and directly contribute cells to the calcifying process in MGP-deficient aortas. These studies support EndMTs as a novel mechanism of EC contributing to vascular calcification [13].

Vascular calcification is a common complication of diabetes mellitus, and increases morbidity and mortality in diabetic patients [14]. Several lineages of vascular cells are known to contribute to diabetic calcification including smooth muscle cells and pericytes [15]. Recently, we demonstrated the presence of cells with EC-origin in calcified lesions in diabetic aortas by lineage tracing [14, 16], suggesting that diabetic endothelium not only produces osteoinductive factors, but directly contributes cells to the calcifying process. The process appears to be driven by bone morphogenetic proteins (BMPs) induced by high glucose in ECs [2, 11, 14], and is
limited by enhanced BMP inhibition [16]. However, it is still unclear how the ECs gain plasticity to undergo osteogenesis in the setting of high glucose.

The \textit{Ins2}^{Akita/wt} mouse is a monogenic diabetic model, and a model of diabetic calcific vasculopathy. The Akita mutation disrupts the two disulfide-bonds of A and B chains, which decreases proinsulin formation and in turn mature insulin [17]. \textit{Ins2}^{Akita/wt} mice become spontaneously diabetic due to the reduced insulin level beginning at 3–4 weeks of age, and has been used as a model for type I diabetes mellitus (DM1) [18].

To determine if EndMTs play a role in calcific vasculopathy in diabetes mellitus, we investigated the emergence of EndMTs in aortic endothelium of \textit{Ins2}^{Akita/wt} mice. We demonstrated that induction of sex determining region Y-box 2 (Sox2) mediated the increased expression of markers for EndMTs in the diabetic endothelium. Limiting endothelial Sox2 reduced the expression of these markers as well as aortic calcification. Our results also supported that a complex of serine proteases was involved in the induction of Sox2. Together, the results suggest that EndMTs contribute to vascular calcification in diabetes mellitus.

Materials and Methods

Animals

\textit{Ins2}^{Akita/+} (C57BL/6-Ins2Akita/J), \textit{Cdh5}^{Cre} (B6.Cg-Tg(Cdh5-cre)7Mlia/J) and \textit{Sox2}^{floxed/floxed} (Sox2tm1.1Lan/J) mice were obtained from the Jackson Laboratory. Genotypes were confirmed by PCR [17, 19, 20], and experiments were performed with generations F4–F6. Littermates were used as wild type controls. All mice were fed a standard chow diet (Diet 8604, HarlanTeklad Laboratory). The studies were reviewed and approved by the Institutional Review Board and conducted in accordance with the animal care guideline set by the University of California, Los Angeles. All procedures were reviewed and approved by the Animal Care Committee (ARC) and the UCLA School of Medicine. The investigation conformed to the National Research Council, Guide for the Care and Use of Laboratory Animals, Eighth Edition (Washington, DC: The National Academies Press, 2011). Diisopropylfluorophosphate (DFP) (Sigma-Aldrich) and serpina1 (Origene) were injected via tail vein or retro-orbital injection (20–50 ng/g, daily) as in previous studies [21, 22]. Injections in \textit{Ins2}^{Akita/+} mice started at 36 weeks of age, and continued for 4 weeks.

The animals were observed once daily during the weeks and once daily on weekends. The parameters that were assessed include the following: weight loss, breathing difficulties, edema, hunched posture, restlessness, vocalizing, impaired mobility, failure to groom and unkempt appearance. The weight was measured and recorded every three days. If the weight decreased by 5%, we measured the weight daily. If the weight decreased by 10%, we euthanized the mouse as per approved protocols. None of the mice died or became ill prior to the experimental endpoints in these studies; 5–30% isoflurane was used for euthanasia of all animals included in these studies.

Tissue culture and CRISPR/Cas9 genomic editing

Human aortic endothelial cells (HAECs) were cultured as previously described [23]. For treatment of HAECs, BMP-4 (40 ng/ml, R&D system) and glucose (22 nmol/L, Sigma-Aldrich) were used as before [11]. For MGP-depletion using CRISPR/Cas9 genomic editing, HAECs were infected by lentiviral vectors, which containing gRNA for exon 1 of the \textit{Mgp} gene and Cas9 (Sigma-Aldrich). The infected cells were selected by puromycin. The positive clones were collected and expanded after 14 days of selection. The depletion of MGP was confirmed by real-time PCR.
RNA analysis

Real-time PCR analysis was performed as previously described [24]. Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was used as a control gene [24]. Primers and probes for mouse MGP, BMP-4, Sox2, Kruppel-like factor 4 (Klf4), snail family zinc finger 2 (Slug or Snail2), stem cell antigen 1 (Sca1), cluster of differentiation (CD)10, and c-kit (also referred to as CD117), were obtained from Applied Biosystems as part of Taqman® Gene Expression Assays.

Pre-sorting of ECs

The pre-sorting of aortic ECs was performed as previously described [11]. Briefly, the aortas were perfused with dispase and enzymatically dispersed. Then, the aortas were dissected into small pieces, and incubated for 45 minutes prior to fixation, staining and FACS analysis.

Immunoblotting

Immunoblotting was performed as previously described [25]. Equal amounts of cellular protein or tissue lysates were used. Blots were incubated with specific antibodies to elastase 1, kallikrein 1 and 6 (all 200 ng/ml; Sigma-Aldrich), elastase 2 (200 ng/ml; Abgent), kallikrein 2 (300 ng/ml; Abgent), kallikrein 5 (300 ng/ml; Acris Antibodies), c-kit (200 ng/ml; Cell Signaling Technology), Sca1 (200 ng/ml; Merck Millipore), CD10 (1:100; ThermoFisher), CD44, CD90 (both 200 ng/ml; Abcam), CD71 (1:200; ThermoFisher), pSMAD1/5/8, Sox2, Klf4, Slug (all 400 ng/ml; Cell Signaling Technology) or total SMAD (400 ng/ml; Santa Cruz Biotechnology). ß-Actin (1:5000 dilution; Sigma-Aldrich) was used as loading control.

Chromatin immunoprecipitation (ChIP) assay

For each ChIP assay, approximately 10^6 cells were crosslinked in 1% formaldehyde for 10 minutes at room temperature. Glycine was added to a concentration of 0.125 M to quench the crosslinking, and the cells were rinsed with ice-cold PBS, resuspended in lysis buffers, and sonicated to shear the crosslinked DNA to fragments ranging from 200–500 bp. Sonication was performed on a Misonix 4000 Sonicator with the samples kept in an ice water bath; 1/10-1/20 of the sonicated lysate was saved for input DNA extraction. The lysate was incubated with 1 μg anti-Sox2 (STEMCELL Technologies) or normal IgG (Abcam) antibodies at 4˚C overnight. After adding 40 μl protein G magnetic beads, the lysate was further incubated for 2–3 hours. The beads were washed with washing buffers repeatedly, after which elution buffer was added and the beads were incubated for 15 minutes at 65˚C. Both the immunoprecipitated and input DNA samples were incubated overnight at 65˚C for reversal of crosslinking. The DNA samples were then purified by sequential phenol: chloroform: isoamyl alcohol (Sigma). The final DNA products were ethanol precipitated and the pellets were air-dried and dissolved in 10 mM Tris-HCl. The real-time PCR was used to detected Sox2 binding sites around the promoters of target genes.

Quantification of aortic calcium

Total aortic calcium was measured using a calcium assay kit (Bioassay) as previously described [26].

Electron microscopy

Transmission electron microscopy (TEM) and scanning electron microscopy (SEM) were performed as described [11].
Statistical analysis

Data were analyzed for statistical significance by ANOVA with post hoc Tukey’s analysis. The analyses were performed using GraphPad Instat©, version 3.0 (GraphPad Software). Data represent mean ± SD. P < 0.05 was considered significant, and experiments were performed a minimum of three times.

Results and Discussion

EndMTs in aortic endothelium of \textit{Ins2}^{Akita/+} mice

We have previously shown that osteogenic cells of endothelial origin contribute to aortic calcification of \textit{Ins2}^{Akita/+} mice [11]. To determine whether ECs undergo EndMTs as part of this process, we examined the aortic endothelium of \textit{Ins2}^{Akita/+} mice at 40 weeks of age, when calcified lesions can be detected in the aortas [11, 14]. Using TEM and SEM, we observed that the internal elastic lamina (IEL), which is in close contact with endothelium, was degraded in the diabetic aortas (Fig 1a, top). The aortic endothelium was replaced by a mixture of cells, which appeared to be penetrating into the medial tissues. In addition, SEM showed what appeared to be ruptures in the diabetic endothelium (Fig 1a, bottom).

To examine whether EndMTs stimulated multipotent characteristics in the \textit{Ins2}^{Akita/+} aortic endothelium, we analyzed the expression of stem cell and mesenchymal markers in isolated

![Fig 1. EndMTs in aortic tissue of \textit{Ins2}^{Akita/+} mice.](image)

(a) Aortic endothelium in \textit{Ins2}^{Akita/+} mice was examined by transmission electron microscopy (TEM) (top) and scanning electron microscopy (SEM) (bottom). Magnification for TEM, 3.7×10^5. Magnification for SEM, 5×10^2. Lu: lumen; IEL: Internal elastic lamina. (b) Expression of mesenchymal stem cell markers and EC marker VE-cadherin (VE-Cad) in CD31-positive and CD45-negative presorted cells from wild type (WT) and \textit{Ins2}^{Akita/+} aortas at 40 weeks of age, as determined by immunoblotting.

doi:10.1371/journal.pone.0167936.g001
aortic ECs by immunoblotting. The EndMT-associated markers Sox2, Klf4, c-kit, Sca1, CD10, CD44, CD71, CD90 and Slug (also known as Snail2) were strongly induced in aortic ECs of Ins2<sup>Akita/+</sup> mice (Fig 1b), while the expression of the EC marker VE-cadherin showed a decrease (Fig 1b). Thus, the results suggest that EndMTs cause a transition of the ECs to a multipotent state, which allows them to contribute cells to the calcifying process [11].

**Limiting Sox2 in ECs reduced EndMTs and vascular calcification in Ins2<sup>Akita/+</sup> mice**

Our previous studies demonstrated that Sox2 induction plays an essential role in EndMTs [2], and Sox2 expression is increased in the endothelium of Ins2<sup>Akita/+</sup> mice (13). To determine whether reducing the levels of endothelial Sox2 would limit the induction of EndMT markers and calcification in Ins2<sup>Akita/+</sup> mice, we bred VE-cadherin (Cdh5)<sup>Cre</sup> and Sox2<sup>flox/flox</sup> mice with Ins2<sup>Akita/+</sup> mice. VE-cadherin-driven Cre expression was previously shown to reduce Sox2 in ECs in the Sox2<sup>flox/flox</sup> mice [2]. We examined the aortic EC of Cdh5<sup>Cre</sup>Sox2<sup>flox/wt</sup>Ins2<sup>Akita/+</sup> mice at 40 weeks of age, and confirmed that Sox2 expression was significantly decreased (Fig 2a and 2b). The endothelial expression of stem cell and mesenchymal markers was decreased as shown by real-time PCR and immunoblotting (Fig 2a and 2b). Furthermore, total aortic calcification was reduced in aortic ECs of Cdh5<sup>Cre</sup>Sox2<sup>flox/wt</sup>Ins2<sup>Akita/+</sup> mice compared to Cdh5<sup>Cre</sup>Sox2<sup>flox/wt</sup>Ins2<sup>+/+</sup> mice (Fig 2c and 2d). These results suggest that limiting Sox2 in ECs reduces EndMTs and vascular calcification in Ins2<sup>Akita/+</sup> mice.

**Fig 2. Limiting Sox2 in endothelium decreases EndMTs and calcification in Ins2<sup>Akita/+</sup> aortas.** (a-b) Decreased expression of Sox2, stem cell and mesenchymal markers in aortas of Cdh5<sup>Cre</sup>Sox2<sup>flox/wt</sup>Ins2<sup>+/+</sup> mice compared to Cdh5<sup>Cre</sup>Sox2<sup>flox/wt</sup>Ins2<sup>+/+</sup> mice, as shown by real-time PCR (a) and immunoblotting (b). VE-cad/VE-cadherin, (c-d) Total aortic calcium and aortic Alizarin red staining of Cdh5<sup>Cre</sup>Sox2<sup>flox/wt</sup>Ins2<sup>+/+</sup> and Cdh5<sup>Cre</sup>Sox2<sup>flox/wt</sup>Ins2<sup>+/+</sup>, Cdh5<sup>Cre</sup>Sox2<sup>flox/flox</sup>Ins2<sup>+/+</sup> and Cdh5<sup>Cre</sup>Sox2<sup>flox/flox</sup>Ins2<sup>+/+</sup> mice. ***p<0.001.

doi:10.1371/journal.pone.0167936.g002
calcium and Alizarin red staining suggested significant improvement of aortic calcification in Cdh5\textsuperscript{Cre}\textsuperscript{Sox2\textsuperscript{flox/wt}} Ins2\textsuperscript{Akita/+} mice. (Fig 2c and 2d). The results suggest that the Sox2 reduction limits EndMTs and vascular calcification in diabetic Ins2\textsuperscript{Akita/+} mice.

Sox2 activates mesenchymal markers in HAECs with excess BMP activity

In previous studies, we demonstrated the induction of both BMP-4 and its inhibitor MGP in the endothelium of Ins2\textsuperscript{Akita/+} mice and glucose-treated human aortic endothelial cells (HAECs) [14]. We also found that excess BMP-4 as well as depletion of MGP triggered EndMTs [14]. However, when comparing the induction of BMP-4 and MGP in response to high glucose, we found a larger relative induction of BMP-4 compared to that of MGP in both the endothelium of Ins2\textsuperscript{Akita/+} mice and glucose-treated HAECs (Fig 3a and 3b). Even though these are relative induction levels, it suggests the MGP level is insufficient to counteract the BMP-4 in hyperglycemic conditions and might explain the Sox2 induction in diabetic conditions.

To confirm that MGP depletion affects Sox2 regulatory activity, as previously reported, we used CRISPR/Cas9 genomic editing system to deplete >99.5% of MGP RNA in HAECs. MGP depletion enhanced BMP signaling as determined by immunoblotting for pSMAD1/5/8 (Fig 3c and 3d). Sox2 and c-kit were induced in MGP-depleted HAECs, and Noggin abolished this induction (Fig 3e), suggesting that excess BMP signaling induce Sox2 to activate EndMTs. We
subsequently performed ChIP assays with enrichment of the DNA by anti-Sox2 antibodies and examined the Sox2 binding sites in promoter regions of CD90 and c-kit by real-time PCR. As expected, the results showed abundant Sox2 binding around the regulatory regions of CD90 and c-kit in MGP-depleted HAECS as compared to controls (Fig 3f). Thus, a reduction of Sox2 would be expected to limit the reduction of EndMT markers.

Up-regulation of serine proteases in aortic endothelium of Ins2^Akita/+ mice

Our previous study demonstrated that a complex of serine proteases, which included elastase 1, 2 and kallikrein 1, 5 and 6, was involved in aortic calcification in MGP-deficient mice [2]. To determine if these proteases were involved in diabetic calcification, we examined expression in isolated aortic ECs from Ins2^Akita/+ mice. The results revealed induction of the same five serine proteases also in diabetes, as determined by immunoblotting (Fig 4a).

To determine whether the induction of these serine proteases could be limited, we bred the Ins2^Akita/+ mice with Mgp^tg/wt mice to suppress BMP activity [27], and examined the protease expression in isolated aortic ECs from Mgp^tg/wt Ins2^Akita/+ mice. The result showed a significant reduction in the expression of elastase 1, 2 and kallikrein 1, 5 and 6, as detected by immunoblotting (Fig 4b), suggesting that the induction involves BMP activation.

Inhibition of serine proteases decreased aortic calcification in Ins2^Akita/+ mice

To determine if we could limit calcification in the Ins2^Akita/+ mice, we treated Ins2^Akita/+ mice with the serine protease inhibitors DFP and serpinA1 for 4 weeks starting at 36 weeks of age.

Fig 4. Induction of elastases and kallikreins in Ins2^Akita/+ aortic endothelium. Expression of ELA 1, 2 and KLK 1, 5, 6 in CD31-positive and CD45-negative presorted cells (a) from wild type (WT) and Ins2^Akita/+ aortas at 40 weeks of age, and (b) from aortas of WT, Ins2^Akita/+, Mgp^tg/wt and Mgp^tg/wt Ins2^Akita/+ mice at 40 weeks of age, as determined by immunoblotting.

doi:10.1371/journal.pone.0167936.g004
We found that total aortic calcium was significantly reduced after DFP or serpina1 treatment (Fig 5a and 5b), suggesting that serine protease inhibitors are effective in limiting calcification. We also analyzed the expression of mesenchymal markers in aortic tissues by immunoblotting, and found significant decreases in Sox2, c-kit, Slug and CD44 in \textit{Ins2\textsuperscript{Akita/+}} aortic ECs after protease inhibition (Fig 5c). We also found that DFP significantly decreased Sox2 induction in MGP-depleted HAECs, but have no effect on BMP activity (Fig 5d and 5e). Together, the results suggest that BMP-induced serine proteases are instrumental in the up-regulation of Sox2 and EndMTs in diabetes.

This study provides evidence that EndMTs contributes to vascular calcification in diabetic mice. Our data demonstrate degradation of IEL, loss of normal EC morphology in the aorta, and expression of mesenchymal stem cell markers. The EndMTs resemble those previously reported in \textit{Mgp\textsuperscript{-/-}} mice, which exhibit extensive arterial calcification [2]. \textit{Ins2\textsuperscript{Akita/+}} and \textit{Mgp\textsuperscript{-/-}} mice share a similar phenotype of arterial medial calcification, which is in part promoted by excess BMP activity albeit through different mechanisms [11, 14]. In \textit{Ins2\textsuperscript{Akita/+}} mice, excess vascular BMP activity results from induction of BMPs and BMP receptors by high glucose levels [14], whereas the excess BMP activity in \textit{Mgp\textsuperscript{-/-}} mice is due to loss of BMP inhibition provided by MGP [28]. The excess BMP activity appears instrumental in inducing serine proteases that in turn activate Sox2 expression in ECs, and ultimately trigger EndMTs.

Recently, EndMTs have been associated with a number of diabetic complications. They have been shown to contribute to diabetic cardiomyopathy [29], diabetic nephropathy [30], diabetes-associated kidney fibrosis [31] and diabetic retinopathy [32] through various signal pathways. In the diabetic aorta, EndMTs are part of the calcific vasculopathy. We argue that
excess vascular BMP activity contribute to at least two steps in the calcific process. BMP-4 is known to enhance stem cell characteristics in various stem cells [33] and activate the plasticity of ECs with the help of proteases and Sox2 [2]. Then, pro-osteogenic BMP2, which is induced in the diabetic media [14], may drive these cells into the osteogenic lineage with progressive calcification [34]. BMP regulation of proteases, Sox2 and EndMTs could also be associated with other diabetic complications, such as diabetic nephropathy, in which BMP5 has been associated with the activation of EndMTs [30] and polymorphism of Sox2 has significant gender-specific effects [35].

Activation of serine proteases, such as elastases and kallikreins, has been associated with vascular diseases. Elastases, a subgroup of serine proteases, break down elastin by cleaving peptide bonds at specific residues such as alanine, glycine, and valine [36]. Elevated activity of elastases promotes endothelial migration [37, 38], and is associated with the progression of pulmonary hypertension [39]. Elastase 2 is highly expressed in atherosclerotic lesions and participates in the degradation of elastin, fragments of which may enhance calcification [40–43]. Kallikreins, another subgroup of serine proteases, are classified according to biological function, as tissues kallikreins, which include kallikrein 1 to 15, and plasma kallikrein [44, 45]. Tissue kallikreins are expressed in endothelial cells and play roles in vascular formation and remodeling [46–48]. They are elevated in diabetes mellitus [49], and promote endothelial invasion in diabetic neovascularization [50–52]. Aortic levels were not documented in these studies. Our results support that complexes of elastases and kallikreins are intimately involved in the alteration of EC fate. However, the specific mechanism of these five proteases is not understood at this time, but may be related to activation of specific receptors or other key proteins in endothelial lineage differentiation.

Conclusions

We show that BMP-induced serine proteases up-regulate Sox2, and Sox2-mediated EndMTs play a critical role in diabetic vascular calcification. Our results show the importance of EndMTs in diabetic vascular calcification, a common clinical problem, and provide information for developing new treatment strategies.

Acknowledgments

Funding for this work was provided in part by NIH grants NS79353, HL30568, HL81397 and HL112839, and the American Heart Association (Western Affiliate).

Author Contributions

Conceptualization: KB YY.
Data curation: PG JY AB LIA KB YY.
Formal analysis: PG JY AB LIA KB YY.
Funding acquisition: KB JY YY.
Investigation: PG JY AB LIA KB YY.
Methodology: PG JY AB LIA KB YY.
Project administration: KB YY.
Resources: PG JY AB LIA KB YY.
Supervision: KB YY.
Validation: PG JY AB LIA KB YY.

Writing – original draft: KB YY.

Writing – review & editing: KB YY.

References
1. Welch-Reardon KM, Wu N, Hughes CC. A role for partial endothelial-mesenchymal transitions in angiogenesis? Arterioscler Thromb Vasc Biol. 2015; 35(2):303–8. doi: 10.1161/ATVBAHA.114.303220 PMID: 25425619

2. Yao J, Guihard PJ, Blazquez-Medela AM, Guo Y, Moon JH, Jumabay M, et al. Serine Protease Activation Essential for Endothelial-Mesenchymal Transition in Vascular Calcification. Circ Res. 2015; 117(9):758–69. doi: 10.1161/CIRCRESAHA.115.306751 PMID: 26265629

3. Thiery JP. Epithelial-mesenchymal transitions in development and pathologies. Current opinion in cell biology. 2003; 15(6):740–6. PMID: 14644200

4. Kalluri R, Neilson EG. Epithelial-mesenchymal transition and its implications for fibrosis. J Clin Invest. 2003; 112(12):1776–84. doi: 10.1172/JCI20530 PMID: 14679171

5. Ranchoux B, Antigny F, Rucker-Martín C, Hautefort A, Pechoux C, Bogaard HJ, et al. Endothelial-to-mesenchymal transition in pulmonary hypertension. Circulation. 2015; 131(11):1006–18. doi: 10.1161/CIRCULATIONAHA.114.008750 PMID: 25593290

6. Chen PY, Qin L, Baeyens N, Li G, Afolabi T, Budatha M, et al. Endothelial-to-mesenchymal transition drives atherosclerosis progression. J Clin Invest. 2015; 125(12):4514–28. doi: 10.1172/JCI82719 PMID: 26517696

7. Kovacic JC, Mercader N, Torres M, Boehm M, Fuster V. Epithelial-to-mesenchymal and endothelial-to-mesenchymal transition: from cardiovascular development to disease. Circulation. 2012; 125(14):1795–808. doi: 10.1161/CIRCULATIONAHA.111.040352 PMID: 22492947

8. Kriz W, Kaisling B, Le Hir M. Epithelial-mesenchymal transition (EMT) in kidney fibrosis: fact or fantasy? J Clin Invest. 2011; 121(2):468–74. doi: 10.1172/JCI44595 PMID: 21370523

9. Medici D, Shore EM, Lounev VY, Kaplan FS, Kalluri R, Olsen BR. Conversion of vascular endothelial cells into multipotent stem-like cells. Nat Med. 2010; 16(12):1400–6. doi: 10.1038/nm.2252 PMID: 21102460

10. Gonzalez DM, Medici D. Signaling mechanisms of the epithelial-mesenchymal transition. Science signaling. 2014; 7(344):re8. doi: 10.1126/scisignal.2005189 PMID: 25249658

11. Yao Y, Jumabay M, Ly A, Radparvar M, Cubberly MR, Bostrom KI. A role for the endothelium in vascular calcification. Circ Res. 2013; 113(5):495–504. doi: 10.1161/CIRCRESAHA.113.301792 PMID: 23852538

12. Luo G, Duy C, McEvee MD, Pinero GJ, Loyer E, Behringer RR, et al. Spontaneous calcification of arteries and cartilage in mice lacking matrix GLA protein. Nature. 1997; 386(6620):78–81. Epub 1997/03/06. doi: 10.1038/386078a0 PMID: 9052783

13. Towler DA. Arteriosclerotic Calcification: A Serpi(n)ginous Path to Cardiovascular Health? Circ Res. 2015; 117(9):744–6. doi: 10.1161/CIRCRESAHA.115.307407 PMID: 26450884

14. Bostrom KI, Jumabay M, Matveyenko A, Nicholas SB, Yao Y. Activation of vascular bone morphogenetic protein signaling in diabetes mellitus. Circ Res. 2011; 108(4):446–57. doi: 10.1161/CIRCRESAHA.110.2193740 PMID: 21659596

15. Sage AP, Tintut Y, Demer LL. Regulatory mechanisms in vascular calcification. Nature reviews Cardiology. 2010; 7(9):528–36. doi: 10.1038/nrcardio.2010.115 PMID: 20664518

16. Yao Y, Bennett BJ, Wang X, Rosenfeld ME, Giachelli C, Lusis AJ, et al. Inhibition of bone morphogenetic proteins protects against atherosclerosis and vascular calcification. Circ Res. 2010; 107(4):485–94. doi: 10.1161/CIRCRESAHA.110.219071 PMID: 20576934

17. Wang J, Takeuchi T, Tanaka S, Kubo SK, Kayo T, Lu D, et al. A mutation in the insulin 2 gene induces diabetes with severe pancreatic beta-cell dysfunction in the Mody mouse. The Journal of clinical investigation. 1999; 103(1):27–37. doi: 10.1172/JCI4431 PMID: 9884331

18. Breyer MD, Bollinger E, Brosius FC 3rd, Coffman TM, Harris RC, Heilig CW, et al. Mouse models of diabetic nephropathy. J Am Soc Nephrol. 2005; 16(1):27–45. doi: 10.1681/ASN.2004080648 PMID: 15563560

19. Alva JA, Zovein AC, Monvoisin A, Murphy T, Salazar A, Harvey NL, et al. VE-Cadherin-Cre-recombinase transgenic mouse: a tool for lineage analysis and gene deletion in endothelial cells. Dev Dyn. 2006; 235(3):759–67. Epub 2006/02/02. doi: 10.1002/dvdy.20643 PMID: 16450386
20. Shaham O, Smith AN, Robinson ML, Taketo MM, Lang RA, Ashery-Padan R. Pax6 is essential for lens fiber cell differentiation. Development. 2009; 136(15):2567–78. doi: 10.1242/dev.032888 PMID: 19570848

21. Stoller JK, Aboussouan LS. Alpha1-antitrypsin deficiency. Lancet. 2005; 365(9478):2225–36. doi: 10.1016/S0140-6736(05)66781-5 PMID: 15978931

22. Lin T, Duek O, Dori A, Kofman O. Differential long term effects of early diisopropylfluorophosphate exposure in Balb/C and C57Bl/J6 mice. International journal of developmental neuroscience: the official journal of the International Society for Developmental Neuroscience. 2012; 30(2):113–20.

23. Yao Y, Zebboudj AF, Shao E, Perez M, Bostrom K. Regulation of bone morphogenetic protein-4 by matrix GLA protein in vascular endothelial cells involves activin-like kinase receptor 1. J Biol Chem. 2006; 281(45):33921–30. Epub 2006/09/05. doi: 10.1074/jbc.M604239200 PMID: 16950789

24. Bostrom K, Zebboudj AF, Yao Y, Lin TS, Torres A. Matrix GLA protein stimulates VEGF expression through increased transforming growth factor-beta1 activity in endothelial cells. J Biol Chem. 2004; 279(51):52904–13. Epub 2004/10/01. doi: 10.1074/jbc.M406688200 PMID: 15456771

25. Yao Y, Jumabay M, Wang A, Bostrom KI. Matrix Gla protein deficiency causes arteriogenous malformations in mice. J Clin Invest. 2011; 121(8):2993–3004. doi: 10.1172/JCI116727 PMID: 21765215

26. Yao Y, Bennett BJ, Wang X, Rosenfeld ME, Giachelli C, Lusis AJ, et al. Inhibition of bone morphogenetic proteins protects against atherosclerosis and vascular calcification. Circ Res. 107(4):485–94. Epub 2010/06/26. doi: 10.1161/CIRCRESAHA.110.219071 PMID: 20576934

27. Yao Y, Nowak S, Yochelis A, Garfinkel A, Bostrom KI. Matrix GLA protein, an inhibitory morphogen in pulmonary vascular development. J Biol Chem. 2007; 282(41):30131–42. Epub 2007/08/03. doi: 10.1074/jbc.M702972200 PMID: 17670744

28. Yao Y, Shahbazian A, Bostrom KI. Proline and gamma-carboxylated glutamate residues in matrix Gla protein are critical for binding of bone morphogenetic protein-4. Circ Res. 2008; 102(9):1065–74. Epub 2008/03/29. doi: 10.1161/CIRCRESAHA.107.166124 PMID: 18396157

29. Feng B, Cao Y, Chen S, Chu X, Chu Y, Chakrabarti S. miR-200b Mediates Endothelial-to-Mesenchymal Transition in Diabetic Cardiomyopathy. Diabetes. 2016; 65(3):768–79. doi: 10.2337/db15-1033 PMID: 26718496

30. Patschan D, Schwarze K, Henze E, Becker JU, Patschan S, Muller GA. eEoC-mediated modulation of endothelial autophagy, senescence, and EnMT in murine diabetic nephropathy. Am J Physiol Renal Physiol. 2014; 307(6):F686–94. doi: 10.1152/ajprenal.00650.2013 PMID: 25080521

31. Nagai T, Kanasaki M, Srivastava SP, Nakamura Y, Ishigaki Y, Kitada M, et al. N-acetyl-serlyl-aspartyl-lysyl-proline inhibits diabetes-associated kidney fibrosis and endothelial-mesenchymal transition. BioMed research international. 2014; 2014:696475. doi: 10.1155/2014/696475 PMID: 24783220

32. Abu El-Asrar AM, De Hertogh G, van den Eynde K, Alam K, Van Raemdonck K, Opdenakker G, et al. Myofibroblasts in proliferative diabetic retinopathy can originate from infiltrating fibrocytes and through endothelial-to-mesenchymal transition (EndoMT). Exp Eye Res. 2015; 132:179–89. doi: 10.1016/j.exer.2015.01.023 PMID: 25637870

33. Bostrom KI, Garfinkel A, Yao Y, Jumabay M. Concise review: applying stem cell biology to vascular structures. Stem Cells. 2012; 30(3):386–91. doi: 10.1002/stem.1027 PMID: 22230604

34. Bostrom K, Watson KE, Horn S, Wortham C, Herman IM, Demer LL. Bone morphogenetic protein expression in human atherosclerotic lesions. J Clin Invest. 1993; 91(4):1800–9. Epub 1993/04/01. doi: 10.1172/JCI116391 PMID: 8473518

35. Gu HF, Alvarsson A, Efendic S, Brismar K. SOX2 has gender-specific genetic effects on diabetic nephropathy in samples from patients with type 1 diabetes mellitus in the GoKinD study. Gender medicine. 2009; 6(4):555–64. doi: 10.1016/j.genm.2009.11.001 PMID: 20114006

36. Bieth JG. [The elastases]. Journal de la Societe de biologie. 2001; 195(2):173–9. PMID: 11723830

37. Cepinskas G, Sandig M, Kvitys PR. PAF-induced elastase-dependent neutrophil transendothelial migration is associated with the mobilization of elastase to the neutrophil surface and localization to the migrating front. J Cell Sci. 1999; 112 (Pt 12):1937–45.

38. Rao RM, Betz TV, Lamont DJ, Kim MB, Shaw SK, Froio RM, et al. Elastase release by transmigrating neutrophils deactivates endothelial-bound SDF-1alpha and attenuates subsequent T lymphocyte transendothelial migration. J Exp Med. 2004; 200(6):713–24. doi: 10.1084/jem.20040499 PMID: 15381727

39. Rabinovitch M. Molecular pathogenesis of pulmonary arterial hypertension. J Clin Invest. 2012; 122(12):4306–13. doi: 10.1172/JCI60658 PMID: 23202738

40. Maurice P, Blaise S, Gayral S, Debeille L, Laffargue M, Homebeck W, et al. Elastin fragmentation and atherosclerosis progression: the elastokine concept. Trends Cardiovasc Med. 2013; 23(6):211–21. doi: 10.1016/j.tcm.2012.12.004 PMID: 23561795
41. Antonicelli F, Bellon G, Debelle L, Hornebeck W. Elastin-elastases and inflammation. Current topics in developmental biology. 2007; 79:99–155. doi: 10.1016/S0070-2153(06)79005-6 PMID: 17498549

42. Khavandgar Z, Roman H, Li J, Lee S, Vaii H, Brinckmann J, et al. Elastin haploinsufficiency impedes the progression of arterial calcification in MGP-deficient mice. J Bone Miner Res. 2013.

43. Sinha A, Vyavahare NR. High-glucose levels and elastin degradation products accelerate osteogenesis in vascular smooth muscle cells. Diabetes & vascular disease research: official journal of the International Society of Diabetes and Vascular Disease. 2013; 10(5):410–9.

44. Emami N, Diamandis EP. Human tissue kallikreins: a road under construction. Clinica chimica acta; international journal of clinical chemistry. 2007; 381(1):78–84. doi: 10.1016/j.cca.2007.02.023 PMID: 17382920

45. Bhoola KD, Figueroa CD, Worthy K. Bioregulation of kinins: kallikreins, kininogens, and kininases. Pharmacological reviews. 1992; 44(1):1–80. PMID: 1313585

46. Yayama K, Kunimatsu N, Teranishi Y, Takano M, Okamoto H. Tissue kallikrein is synthesized and secreted by human vascular endothelial cells. Biochim Biophys Acta. 2003; 1593(2–3):231–8. PMID: 12581867

47. Aimes RT, Zijlstra A, Hooper JD, Ogbourne SM, Sit ML, Fuchs S, et al. Endothelial cell serine proteases expressed during vascular morphogenesis and angiogenesis. Thromb Haemost. 2003; 89(3):561–72. PMID: 12624642

48. Azizi M, Boutouyrie P, Bissery A, Agharazii M, Verbeke F, Stern N, et al. Arterial and renal consequences of partial genetic deficiency in tissue kallikrein activity in humans. J Clin Invest. 2005; 115(3):780–7. doi: 10.1172/JCI23669 PMID: 15765151

49. Campbell DJ, Kladis A, Zhang Y, Jenkins AJ, Prior DL, Yi M, et al. Increased tissue kallikrein levels in type 2 diabetes. Diabetologia. 2010; 53(4):779–85. PMID: 20225398

50. Spinetti G, Fortunato O, Cordella D, Portararo P, Krankel N, Katare R, et al. Tissue kallikrein is essential for invasive capacity of circulating proangiogenic cells. Circ Res. 2011; 108(3):284–93. doi: 10.1161/CIRCRESAHA.110.236786 PMID: 21164105

51. Emanueli C, Minasi A, Zacheo A, Chao J, Chao L, Salis MB, et al. Local delivery of human tissue kallikrein gene accelerates spontaneous angiogenesis in mouse model of hindlimb ischemia. Circulation. 2001; 103(1):125–32. PMID: 11136697

52. Stone OA, Richer C, Emanueli C, van Weel V, Quax PH, Katare R, et al. Critical role of tissue kallikrein in vessel formation and maturation: implications for therapeutic revascularization. Arterioscler Thromb Vasc Biol. 2009; 29(5):657–64. doi: 10.1161/ATVBAHA.108.182139 PMID: 19164804